Scorpius Holdings Partners with BARDA for Health Initiatives
DURHAM, N.C. — Scorpius Holdings, Inc. (NYSE American: SCPX) is thrilled to announce its participation in the Rapid Response Partnership Vehicle (RRPV), a program initiated by the Biomedical Advanced Research and Development Authority (BARDA). This collaboration is focused on accelerating the development of medical countermeasures (MCMs) that are essential for addressing biological threats, such as pandemic influenza and other infectious diseases.
The Importance of RRPV
The RRPV plays a crucial role in supporting BARDA’s mission by fostering collaboration among various federal partners. Through this initiative, Scorpius is poised to contribute significantly to the development of MCM products and technologies, particularly in vaccines and therapeutics. With its advanced biomanufacturing capabilities, Scorpius is uniquely positioned to assist government agencies in their ongoing efforts to tackle public health emergencies.
Scorpius’ Dedication to Public Health
Jeff Wolf, CEO of Scorpius Holdings, expressed his pride in being selected for the RRPV, stating, “This opportunity enables us to leverage our manufacturing capabilities to support BARDA and the groups that serve the US government.” The team's goal is to enhance the speed and efficiency of developing medical countermeasures, ultimately safeguarding public health and strengthening national security.
Scorpius Holdings: A Leader in Biomanufacturing
Scorpius is renowned for its cutting-edge production facilities that specialize in the creation of biological products. The company provides both customized and standardized solutions for biopharmaceutical development. Its flexible manufacturing platform allows for a rapid response to emerging health threats, positioning Scorpius as a key player in the dynamic field of public health.
Preparing for Future Health Emergencies
By joining the RRPV, Scorpius is gearing up to address future public health challenges, including pandemics and other biological threats. This collaboration with BARDA emphasizes a shared commitment to ensuring readiness and effectiveness in responding to potential health crises.
BARDAs Essential Mission
BARDAs role within the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) is vital for advancing the development of vaccines, drugs, and diagnostic tools aimed at combating health security threats. Scorpius’s inclusion in the RRPV showcases its capacity for innovation in a rapidly evolving biomanufacturing landscape.
The Future of Scorpius Holdings
Scorpius Holdings, an integrated contract development and manufacturing organization (CDMO), is committed to advancing biologic and cell therapy programs into clinical applications. The company offers a comprehensive array of analytical, development, and manufacturing services tailored to pharmaceutical and biotech firms, all from its modern facilities located in San Antonio, TX.
The experienced team at Scorpius prioritizes transparent collaborations and high-quality biologics manufacturing, aiming to deliver flexible solutions that meet the diverse needs of its partners. With the rapid growth of biologics and an increasing focus on health security, Scorpius is well-positioned to lead advancements in this vital field.
Media and Investor Relations
For those interested in following Scorpius Holdings, the company invites you to reach out to David Waldman for media inquiries and investor relations at +1 919 289 4017, or contact via email at ir@scorpiusbiologics.com.
Frequently Asked Questions
What is the Rapid Response Partnership Vehicle (RRPV)?
The RRPV is an initiative by BARDA aimed at enhancing the development of medical countermeasures, particularly during public health emergencies.
How does Scorpius Holdings contribute to biomanufacturing?
Scorpius Holdings employs its advanced biomanufacturing capabilities to develop vaccines and therapeutics as part of its collaboration with BARDA.
Where are Scorpius’s facilities located?
Scorpius operates state-of-the-art facilities in San Antonio, TX, designed to meet a variety of biopharmaceutical needs.
What role does BARDA play in public health?
BARDAs mission is to facilitate the development of medical countermeasures to combat various health security threats, including infectious diseases.
How can I contact Scorpius Holdings for more information?
To inquire about media and investor relations, contact David Waldman at +1 919 289 4017 or via email at ir@scorpiusbiologics.com.
